Kirurgian vastuualue

Julkaisut 2019 (alustava)
Publications 2019 (preliminary)

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Assel M et al. A Four-kallikrein Panel and ß-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
2 Booth N et al. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
3 Caetano Dos Santos F et al. VASIM: an automated tool for the quantification of carotid atherosclerosis by computed tomography angiography.
4 Carlsson S et al. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
5 Fizazi K et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
6 Hackman G et al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
7 Horwich A et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees.
8 Hugosson J et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
9 Häkkinen MR et al. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue.
10 Jambor I et al. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
11 Joentausta R, Murtola T. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591.
12 Joentausta R et al. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
13 Kaipia A. Erektio ja hermostollinen säätely.
14 Kaipia A. Erektiohäiriössä käytettävät lääkeaineet.
15 Khan J et al. Lower incidence of late tamponade after cardiac surgery by extended chest tube drainage.
16 Kiiski J et al. Transverse myocutaneous gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results.
17 Kiiski J et al. Tranverse myocutaneus gracilis flap reconstruction is feasible after pelvic exenteration: 12-year surgical and oncological results.
18 Kinnunen PT et al. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.
19 Knaapila J et al. Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort.
20 Knuuttila E et al. Access and concentrations of atorvastatin in the prostate in men with prostate cancer.
21 Kukko V et al. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
22 Li-Sheng Chen S et al. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
23 Lindberg A et al. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer.
24 Lindström I et al. Psoas Muscle Area and Quality Are Independent Predictors of Survival in Patients Treated for Abdominal Aortic Aneurysms.
25 Linnanmäki L. The Biomechanical Properties of Flexor Tendon Repairs.
26 Murtola T et al. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
27 Murtola T et al. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind....
28 Murtola T et al. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
29 Murtola TJ, Veitonmäki T. Aspirin and Prostate Cancer Mortality: The Role of Tumor Grading Misclassification?
30 Nissinen SI et al. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis.
31 Nuotio M et al. Elevated post-void residual volume in a geriatric post-hip fracture assessment in women-associated factors and risk of mortality.
32 Nurminen P et al. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment.
33 Oksala N et al. Pre-Operative Masseter Area is an Independent Predictor of Long-Term Survival after Carotid Endarterectomy.
34 Pakarainen T et al. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
35 Peltokangas M et al. Lower Limb Pulse Rise Time as a Marker of Peripheral Arterial Disease.
36 Pelttari S et al. Pseudoxanthoma elasticum - pyrofosfaatin puutostauti.
37 Pesonen J. Course and Consequences of Nocturia.
38 Pylväläinen J et al. Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time.
39 Rantalaiho I et al. Acute kidney injury following hip fracture.
40 Saarimäki L et al. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
41 Santala E et al. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland - A nationwide cohort study.
42 Santala EE et al. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland.
43 Schumacher FR et al. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
44 Shore N et al. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
45 Siltari A et al. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study.
46 Sujenthiran A et al. Is Nonoperative Management the Best First-line Option for High-grade Renal trauma? A Systematic Review.
47 Sutinen M et al. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry.
48 Sutinen M et al. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry.
49 Syyli N et al. Left ventricular ejection fraction adds value over the GRACE score in prediction of 6-month mortality after ACS: the MADDEC study.
50 Talvitie A et al. Factors related to self-rated health and life satisfaction one year after radical prostatectomy for localised prostate cancer: a cross-sectional survey.
51 Vakhitov D et al. Survival of Patients and Treatment-Related Outcome After Intra-Arterial Thrombolysis for Acute Lower Limb Ischemia.
52 Vandekerkhove G et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
53 Åkerla J et al. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men.
54 Østergren P et al. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.

Julkaisutietokanta 6.4.2020 Publications Data Base 6.4.2020